Glimstep MP 2mg/500mg/15mg Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. This combination targets multiple pathophysiological defects in type 2 diabetes, providing improved glycemic control compared to monotherapy. Glimstep MP is typically prescribed when diet, exercise, and monotherapy with either agent do not achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and assess renal and hepatic function during therapy. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. Caution is advised in patients with heart failure or hepatic impairment. Glimstep MP should be used under medical supervision, with dosage adjustments based on therapeutic response and tolerability to optimize diabetes management and reduce the risk of complications.

Dosage & How to Use